| Literature DB >> 35793042 |
Anna Zerdoug1,2, Marc Le Vée1, Shotaro Uehara3, Béatrice Lopez2, Christophe Chesné2, Hiroshi Suemizu3, Olivier Fardel4.
Abstract
Chimeric mice with humanized livers constitute an attractive emergent experimental model for investigating human metabolism and disposition of drugs. The present review was designed to summarize key findings about the use of this model for studying human hepatic drug transporters, which are now recognized as important players in pharmacokinetics and consequently have to be considered from a regulatory perspective during pharmaceutical drug development. The reviewed data indicate that chimeric mice with humanized livers have been successfully used for analysing the implications of human hepatic drug transporters for drug hepatobiliary elimination, drug-drug interactions and drug-induced cholestasis. Such transporter studies have been performed in vivo with chimeric mice and/or in vitro with human hepatocytes isolated from humanized liver and used either in suspension or in culture. The residual presence of mouse hepatocytes and the potential morphological/histological alterations of the humanized liver, as well as its immunodeficient mouse environment, have, however, to be considered when using chimeric mice with humanized livers for transporter studies. Finally, if the proof of concept of applying chimeric mice with humanized livers to hepatic drug transport is established, more experimental data on this topic, including from standardization approaches, are likely required to completely and accurately demonstrate the robustness, convenience and added value of this chimeric mouse model for drug transporter studies.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35793042 DOI: 10.1007/s13318-022-00782-9
Source DB: PubMed Journal: Eur J Drug Metab Pharmacokinet ISSN: 0378-7966 Impact factor: 2.569